exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087573 RNA Name: hsa-miR-92a-3p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 134169544 End Site(bp): 134169565 External Links: hsa-miR-92a-3p

Disease Information

Disease Name: Moyamoya Disease Disease Category: Nervous System Diseases MeSH ID: D009072 Type: Diseases Category/Nervous System Diseases Alias: Progressive Intracranial Occlusive Arteropathy (Moyamoya)//Moyamoya Syndrome//Moya-Moya Disease//Disease, Moya-Moya//Moya Moya Disease//Cerebrovascular Moyamoya Disease//Moyamoya Disease, Primary//Disease, Primary Moyamoya//Moyamoya Diseases, Primary//Primary Moyamoya Disease//Primary Moyamoya Diseases//Moyamoya Disease, Classic//Classic Moyamoya Disease//Disease, Classic Moyamoya//Moyamoya Disease, Secondary//Secondary Moyamoya Disease

Expression Detail

GEO ID: GSE100488 Description: Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins Experimental Design: Disease vs Control Case Disease Type: Moyamoya Disease Case Disease SubType: NA Case Sample: Moyamoya Disease Control Sample: Normal Number of Case: 11 Number of Control: 10 Number of Samples: 21

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MAZ chr16 29806106 29811164 + RPS8 chr1 44775251 44778779 + ESRP1 chr8 94641074 94707466 + PTPRZ1 chr7 121873089 122062036 + YIPF3 chr6 43511832 43516985 - SEC63 chr6 107867756 107958208 - NPM1 chr5 171387116 171411137 + USP21 chr1 161159450 161165723 + ZNF330 chr4 141220887 141234697 + HBE1 chr11 5268345 5505652 - EHMT2 chr6 31879759 31897687 - PITPNA chr17 1517718 1562792 - RBBP5 chr1 205086142 205122015 - PNKD chr2 218270392 218346793 + SMC1A chrX 53374149 53422728 - RWDD1 chr6 116571409 116597675 + GLCE chr15 69160584 69272217 + CEP89 chr19 32875925 32971991 - PPP3CB chr10 73436428 73496024 - HMGB1 chr13 30456704 30617597 - KLF4 chr9 107484852 107490482 - MRPS16 chr10 73248843 73252693 - TCP1 chr6 159778498 159789703 - EZR chr6 158765741 158819368 - PSMB8 chr6 32840717 32844679 - RPL17-C18orf32 chr18 49481681 49492479 - OGFOD1 chr16 56451521 56479104 + MCM3 chr6 52264014 52284881 - EIF4G2 chr11 10797050 10808940 - RPL13A chr19 49487554 49492308 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001414 chr4 56277780 56284152 + hsa_circ_0000126 chr1 150997086 150999803 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC074117.1 chr2 27356246 27367622 + AC130650.2 chr16 14150833 14153235 + DAPK1-IT1 chr9 87553454 87554459 + LINC01128 chr1 825138 859446 + MALAT1 chr11 65497688 65506516 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + PITPNA-AS1 chr17 1516931 1518096 + PURPL chr5 27217714 27496994 + SNHG5 chr6 85650491 85678932 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE100488 Sample Source: Blood Source Fraction: Plasma Platform: GPL20712 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 291 Sample treatment protocol: Whole blood samples were collected into disodium ethylenediaminotetraacetate tubes, centrifuged (4 °C, 3000 rpm, 30 minutes) immediately for plasma. RNA Extract protocol: Total RNA was isolated from 200 uL of the pooled plasma using miRNeasy Serum/Plasma Kit (QIAGEN, Hilden, Germany). RNA library preparation protocol: Cyanine 3-pCp-labeled microRNA was prepared from 2-uL of total RNA isolated from 200-uL of plasma, using Agilent's miRNA Complete Labeling and Hyb Kit (part number 5190-0456).

Reference

PMID: 30157848 Title: Circulating miRNome profiling in Moyamoya disease-discordant monozygotic twins and endothelial microRNA expression analysis using iPS cell line Author: Uchino H, Ito M, Kazumata K, Hama Y, Hamauchi S, Terasaka S, Sasaki H, Houkin K Journal: BMC Med Genomics. 2018 Aug 29;11(1):72. Description: we employed a disease discordant monozygotic twin-based study design to unmask potential confounders.